Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice
Mer receptor tyrosine kinase (Mer) regulates macrophage activation and promotes apoptotic cell clearance. Mer activation is regulated through proteolytic cleavage of the extracellular domain. To determine if membrane-bound Mer is cleaved during bleomycin-induced lung injury, and, if so, how preventi...
Gespeichert in:
Veröffentlicht in: | Toxicology and applied pharmacology 2012-08, Vol.263 (1), p.61-72 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 72 |
---|---|
container_issue | 1 |
container_start_page | 61 |
container_title | Toxicology and applied pharmacology |
container_volume | 263 |
creator | Lee, Ye-Ji Lee, Seung-Hae Youn, Young-So Choi, Ji-Yeon Song, Keung-Sub Cho, Min-Sun Kang, Jihee Lee |
description | Mer receptor tyrosine kinase (Mer) regulates macrophage activation and promotes apoptotic cell clearance. Mer activation is regulated through proteolytic cleavage of the extracellular domain. To determine if membrane-bound Mer is cleaved during bleomycin-induced lung injury, and, if so, how preventing the cleavage of Mer enhances apoptotic cell uptake and down-regulates pulmonary immune responses. During bleomycin-induced acute lung injury in mice, membrane-bound Mer expression decreased, but production of soluble Mer and activity as well as expression of disintegrin and metalloproteinase 17 (ADAM17) were enhanced . Treatment with the ADAM inhibitor TAPI-0 restored Mer expression and diminished soluble Mer production. Furthermore, TAPI-0 increased Mer activation in alveolar macrophages and lung tissue resulting in enhanced apoptotic cell clearance in vivo and ex vivo by alveolar macrophages. Suppression of bleomycin-induced pro-inflammatory mediators, but enhancement of hepatocyte growth factor induction were seen after TAPI-0 treatment. Additional bleomycin-induced inflammatory responses reduced by TAPI-0 treatment included inflammatory cell recruitment into the lungs, levels of total protein and lactate dehydrogenase activity in bronchoalveolar lavage fluid, as well as caspase-3 and caspase-9 activity and alveolar epithelial cell apoptosis in lung tissue. Importantly, the effects of TAPI-0 on bleomycin-induced inflammation and apoptosis were reversed by coadministration of specific Mer-neutralizing antibodies. These findings suggest that restored membrane-bound Mer expression by TAPI-0 treatment may help resolve lung inflammation and apoptosis after bleomycin treatment.
►Mer expression is restored by TAPI-0 treatment in bleomycin-stimulated lung. ►Mer signaling is enhanced by TAPI-0 treatment in bleomycin-stimulated lung. ►TAPI-0 enhances efferocytosis and promotes resolution of lung injury. |
doi_str_mv | 10.1016/j.taap.2012.05.024 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22215882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041008X12002499</els_id><sourcerecordid>22687607</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-55fb5f1013f68e0a3f94b30913ea8a1671f8daa9d515769bd818367ebcaa7ded3</originalsourceid><addsrcrecordid>eNp9kc2KFDEURoMoTtv6Ai4kIC6rvUnqJwVuZBgdYUQXCu5CKrkZ01RViiTV0G9vih51N6sbyPkuX04Iec3gwIC174-HrPVy4MD4AZoD8PoJ2THo2wqEEE_JDqBmFYD8dUVepHQEgL6u2XNyxXkruxa6HRm_RzzhnP18T82I-qTvkQZHv2KkSwxTyJgoOocxmHMOySeqZ0vTuiwRUyqX2qwZ6biWBX4-rvFcBh1GDNPZlFOOqDNaOnmDL8kzp8eErx7mnvz8dPPj-ra6-_b5y_XHu8rUrM5V07ihceWJwrUSQQvX14OAngnUUrO2Y05arXvbsKZr-8FKJkXb4WC07ixasSdvL3tDyl4l4zOa3ybMM5qsOOeskZIXil8oE0NKEZ1aop90PCsGahOsjmoTrDbBChpVBJfQm0toWYcJ7b_IX6MFePcA6GT06KKejU__uVYwKcv_7MmHC4dFxMlj3HribND6uNW0wT_W4w_ObZs1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lee, Ye-Ji ; Lee, Seung-Hae ; Youn, Young-So ; Choi, Ji-Yeon ; Song, Keung-Sub ; Cho, Min-Sun ; Kang, Jihee Lee</creator><creatorcontrib>Lee, Ye-Ji ; Lee, Seung-Hae ; Youn, Young-So ; Choi, Ji-Yeon ; Song, Keung-Sub ; Cho, Min-Sun ; Kang, Jihee Lee</creatorcontrib><description>Mer receptor tyrosine kinase (Mer) regulates macrophage activation and promotes apoptotic cell clearance. Mer activation is regulated through proteolytic cleavage of the extracellular domain. To determine if membrane-bound Mer is cleaved during bleomycin-induced lung injury, and, if so, how preventing the cleavage of Mer enhances apoptotic cell uptake and down-regulates pulmonary immune responses. During bleomycin-induced acute lung injury in mice, membrane-bound Mer expression decreased, but production of soluble Mer and activity as well as expression of disintegrin and metalloproteinase 17 (ADAM17) were enhanced . Treatment with the ADAM inhibitor TAPI-0 restored Mer expression and diminished soluble Mer production. Furthermore, TAPI-0 increased Mer activation in alveolar macrophages and lung tissue resulting in enhanced apoptotic cell clearance in vivo and ex vivo by alveolar macrophages. Suppression of bleomycin-induced pro-inflammatory mediators, but enhancement of hepatocyte growth factor induction were seen after TAPI-0 treatment. Additional bleomycin-induced inflammatory responses reduced by TAPI-0 treatment included inflammatory cell recruitment into the lungs, levels of total protein and lactate dehydrogenase activity in bronchoalveolar lavage fluid, as well as caspase-3 and caspase-9 activity and alveolar epithelial cell apoptosis in lung tissue. Importantly, the effects of TAPI-0 on bleomycin-induced inflammation and apoptosis were reversed by coadministration of specific Mer-neutralizing antibodies. These findings suggest that restored membrane-bound Mer expression by TAPI-0 treatment may help resolve lung inflammation and apoptosis after bleomycin treatment.
►Mer expression is restored by TAPI-0 treatment in bleomycin-stimulated lung. ►Mer signaling is enhanced by TAPI-0 treatment in bleomycin-stimulated lung. ►TAPI-0 enhances efferocytosis and promotes resolution of lung injury.</description><identifier>ISSN: 0041-008X</identifier><identifier>EISSN: 1096-0333</identifier><identifier>DOI: 10.1016/j.taap.2012.05.024</identifier><identifier>PMID: 22687607</identifier><identifier>CODEN: TXAPA9</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; ACETATES ; Acute Lung Injury - chemically induced ; Acute Lung Injury - prevention & control ; ADAM Proteins - drug effects ; ADAM Proteins - metabolism ; ADAM17 Protein ; Animals ; Antibiotics, Antineoplastic - pharmacology ; APOPTOSIS ; Apoptosis - drug effects ; Apoptotic cell clearance ; Biological and medical sciences ; BLEOMYCIN ; Bleomycin - pharmacology ; Blotting, Western ; Caspase 3 - metabolism ; Caspase 9 - drug effects ; CLEARANCE ; Dipeptides - pharmacology ; DNA Damage - drug effects ; ENZYME IMMUNOASSAY ; Enzyme-Linked Immunosorbent Assay ; GROWTH FACTORS ; Hydroxamic Acids - pharmacology ; INFLAMMATION ; INJURIES ; LACTATE DEHYDROGENASE ; Lung injury ; LUNGS ; MACROPHAGES ; Male ; Medical sciences ; Mer receptor tyrosine kinase ; MICE ; Mice, Inbred C57BL ; Phagocytosis - drug effects ; Receptor Protein-Tyrosine Kinases - drug effects ; Receptor Protein-Tyrosine Kinases - metabolism ; Receptor Protein-Tyrosine Kinases - physiology ; RECEPTORS ; Reverse Transcriptase Polymerase Chain Reaction ; TAPI-0 ; Toxicology ; TYROSINE</subject><ispartof>Toxicology and applied pharmacology, 2012-08, Vol.263 (1), p.61-72</ispartof><rights>2012 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-55fb5f1013f68e0a3f94b30913ea8a1671f8daa9d515769bd818367ebcaa7ded3</citedby><cites>FETCH-LOGICAL-c414t-55fb5f1013f68e0a3f94b30913ea8a1671f8daa9d515769bd818367ebcaa7ded3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.taap.2012.05.024$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26318803$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22687607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22215882$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Ye-Ji</creatorcontrib><creatorcontrib>Lee, Seung-Hae</creatorcontrib><creatorcontrib>Youn, Young-So</creatorcontrib><creatorcontrib>Choi, Ji-Yeon</creatorcontrib><creatorcontrib>Song, Keung-Sub</creatorcontrib><creatorcontrib>Cho, Min-Sun</creatorcontrib><creatorcontrib>Kang, Jihee Lee</creatorcontrib><title>Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice</title><title>Toxicology and applied pharmacology</title><addtitle>Toxicol Appl Pharmacol</addtitle><description>Mer receptor tyrosine kinase (Mer) regulates macrophage activation and promotes apoptotic cell clearance. Mer activation is regulated through proteolytic cleavage of the extracellular domain. To determine if membrane-bound Mer is cleaved during bleomycin-induced lung injury, and, if so, how preventing the cleavage of Mer enhances apoptotic cell uptake and down-regulates pulmonary immune responses. During bleomycin-induced acute lung injury in mice, membrane-bound Mer expression decreased, but production of soluble Mer and activity as well as expression of disintegrin and metalloproteinase 17 (ADAM17) were enhanced . Treatment with the ADAM inhibitor TAPI-0 restored Mer expression and diminished soluble Mer production. Furthermore, TAPI-0 increased Mer activation in alveolar macrophages and lung tissue resulting in enhanced apoptotic cell clearance in vivo and ex vivo by alveolar macrophages. Suppression of bleomycin-induced pro-inflammatory mediators, but enhancement of hepatocyte growth factor induction were seen after TAPI-0 treatment. Additional bleomycin-induced inflammatory responses reduced by TAPI-0 treatment included inflammatory cell recruitment into the lungs, levels of total protein and lactate dehydrogenase activity in bronchoalveolar lavage fluid, as well as caspase-3 and caspase-9 activity and alveolar epithelial cell apoptosis in lung tissue. Importantly, the effects of TAPI-0 on bleomycin-induced inflammation and apoptosis were reversed by coadministration of specific Mer-neutralizing antibodies. These findings suggest that restored membrane-bound Mer expression by TAPI-0 treatment may help resolve lung inflammation and apoptosis after bleomycin treatment.
►Mer expression is restored by TAPI-0 treatment in bleomycin-stimulated lung. ►Mer signaling is enhanced by TAPI-0 treatment in bleomycin-stimulated lung. ►TAPI-0 enhances efferocytosis and promotes resolution of lung injury.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>ACETATES</subject><subject>Acute Lung Injury - chemically induced</subject><subject>Acute Lung Injury - prevention & control</subject><subject>ADAM Proteins - drug effects</subject><subject>ADAM Proteins - metabolism</subject><subject>ADAM17 Protein</subject><subject>Animals</subject><subject>Antibiotics, Antineoplastic - pharmacology</subject><subject>APOPTOSIS</subject><subject>Apoptosis - drug effects</subject><subject>Apoptotic cell clearance</subject><subject>Biological and medical sciences</subject><subject>BLEOMYCIN</subject><subject>Bleomycin - pharmacology</subject><subject>Blotting, Western</subject><subject>Caspase 3 - metabolism</subject><subject>Caspase 9 - drug effects</subject><subject>CLEARANCE</subject><subject>Dipeptides - pharmacology</subject><subject>DNA Damage - drug effects</subject><subject>ENZYME IMMUNOASSAY</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>GROWTH FACTORS</subject><subject>Hydroxamic Acids - pharmacology</subject><subject>INFLAMMATION</subject><subject>INJURIES</subject><subject>LACTATE DEHYDROGENASE</subject><subject>Lung injury</subject><subject>LUNGS</subject><subject>MACROPHAGES</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mer receptor tyrosine kinase</subject><subject>MICE</subject><subject>Mice, Inbred C57BL</subject><subject>Phagocytosis - drug effects</subject><subject>Receptor Protein-Tyrosine Kinases - drug effects</subject><subject>Receptor Protein-Tyrosine Kinases - metabolism</subject><subject>Receptor Protein-Tyrosine Kinases - physiology</subject><subject>RECEPTORS</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>TAPI-0</subject><subject>Toxicology</subject><subject>TYROSINE</subject><issn>0041-008X</issn><issn>1096-0333</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2KFDEURoMoTtv6Ai4kIC6rvUnqJwVuZBgdYUQXCu5CKrkZ01RViiTV0G9vih51N6sbyPkuX04Iec3gwIC174-HrPVy4MD4AZoD8PoJ2THo2wqEEE_JDqBmFYD8dUVepHQEgL6u2XNyxXkruxa6HRm_RzzhnP18T82I-qTvkQZHv2KkSwxTyJgoOocxmHMOySeqZ0vTuiwRUyqX2qwZ6biWBX4-rvFcBh1GDNPZlFOOqDNaOnmDL8kzp8eErx7mnvz8dPPj-ra6-_b5y_XHu8rUrM5V07ihceWJwrUSQQvX14OAngnUUrO2Y05arXvbsKZr-8FKJkXb4WC07ixasSdvL3tDyl4l4zOa3ybMM5qsOOeskZIXil8oE0NKEZ1aop90PCsGahOsjmoTrDbBChpVBJfQm0toWYcJ7b_IX6MFePcA6GT06KKejU__uVYwKcv_7MmHC4dFxMlj3HribND6uNW0wT_W4w_ObZs1</recordid><startdate>20120815</startdate><enddate>20120815</enddate><creator>Lee, Ye-Ji</creator><creator>Lee, Seung-Hae</creator><creator>Youn, Young-So</creator><creator>Choi, Ji-Yeon</creator><creator>Song, Keung-Sub</creator><creator>Cho, Min-Sun</creator><creator>Kang, Jihee Lee</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>OTOTI</scope></search><sort><creationdate>20120815</creationdate><title>Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice</title><author>Lee, Ye-Ji ; Lee, Seung-Hae ; Youn, Young-So ; Choi, Ji-Yeon ; Song, Keung-Sub ; Cho, Min-Sun ; Kang, Jihee Lee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-55fb5f1013f68e0a3f94b30913ea8a1671f8daa9d515769bd818367ebcaa7ded3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>ACETATES</topic><topic>Acute Lung Injury - chemically induced</topic><topic>Acute Lung Injury - prevention & control</topic><topic>ADAM Proteins - drug effects</topic><topic>ADAM Proteins - metabolism</topic><topic>ADAM17 Protein</topic><topic>Animals</topic><topic>Antibiotics, Antineoplastic - pharmacology</topic><topic>APOPTOSIS</topic><topic>Apoptosis - drug effects</topic><topic>Apoptotic cell clearance</topic><topic>Biological and medical sciences</topic><topic>BLEOMYCIN</topic><topic>Bleomycin - pharmacology</topic><topic>Blotting, Western</topic><topic>Caspase 3 - metabolism</topic><topic>Caspase 9 - drug effects</topic><topic>CLEARANCE</topic><topic>Dipeptides - pharmacology</topic><topic>DNA Damage - drug effects</topic><topic>ENZYME IMMUNOASSAY</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>GROWTH FACTORS</topic><topic>Hydroxamic Acids - pharmacology</topic><topic>INFLAMMATION</topic><topic>INJURIES</topic><topic>LACTATE DEHYDROGENASE</topic><topic>Lung injury</topic><topic>LUNGS</topic><topic>MACROPHAGES</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mer receptor tyrosine kinase</topic><topic>MICE</topic><topic>Mice, Inbred C57BL</topic><topic>Phagocytosis - drug effects</topic><topic>Receptor Protein-Tyrosine Kinases - drug effects</topic><topic>Receptor Protein-Tyrosine Kinases - metabolism</topic><topic>Receptor Protein-Tyrosine Kinases - physiology</topic><topic>RECEPTORS</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>TAPI-0</topic><topic>Toxicology</topic><topic>TYROSINE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Ye-Ji</creatorcontrib><creatorcontrib>Lee, Seung-Hae</creatorcontrib><creatorcontrib>Youn, Young-So</creatorcontrib><creatorcontrib>Choi, Ji-Yeon</creatorcontrib><creatorcontrib>Song, Keung-Sub</creatorcontrib><creatorcontrib>Cho, Min-Sun</creatorcontrib><creatorcontrib>Kang, Jihee Lee</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>OSTI.GOV</collection><jtitle>Toxicology and applied pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Ye-Ji</au><au>Lee, Seung-Hae</au><au>Youn, Young-So</au><au>Choi, Ji-Yeon</au><au>Song, Keung-Sub</au><au>Cho, Min-Sun</au><au>Kang, Jihee Lee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice</atitle><jtitle>Toxicology and applied pharmacology</jtitle><addtitle>Toxicol Appl Pharmacol</addtitle><date>2012-08-15</date><risdate>2012</risdate><volume>263</volume><issue>1</issue><spage>61</spage><epage>72</epage><pages>61-72</pages><issn>0041-008X</issn><eissn>1096-0333</eissn><coden>TXAPA9</coden><abstract>Mer receptor tyrosine kinase (Mer) regulates macrophage activation and promotes apoptotic cell clearance. Mer activation is regulated through proteolytic cleavage of the extracellular domain. To determine if membrane-bound Mer is cleaved during bleomycin-induced lung injury, and, if so, how preventing the cleavage of Mer enhances apoptotic cell uptake and down-regulates pulmonary immune responses. During bleomycin-induced acute lung injury in mice, membrane-bound Mer expression decreased, but production of soluble Mer and activity as well as expression of disintegrin and metalloproteinase 17 (ADAM17) were enhanced . Treatment with the ADAM inhibitor TAPI-0 restored Mer expression and diminished soluble Mer production. Furthermore, TAPI-0 increased Mer activation in alveolar macrophages and lung tissue resulting in enhanced apoptotic cell clearance in vivo and ex vivo by alveolar macrophages. Suppression of bleomycin-induced pro-inflammatory mediators, but enhancement of hepatocyte growth factor induction were seen after TAPI-0 treatment. Additional bleomycin-induced inflammatory responses reduced by TAPI-0 treatment included inflammatory cell recruitment into the lungs, levels of total protein and lactate dehydrogenase activity in bronchoalveolar lavage fluid, as well as caspase-3 and caspase-9 activity and alveolar epithelial cell apoptosis in lung tissue. Importantly, the effects of TAPI-0 on bleomycin-induced inflammation and apoptosis were reversed by coadministration of specific Mer-neutralizing antibodies. These findings suggest that restored membrane-bound Mer expression by TAPI-0 treatment may help resolve lung inflammation and apoptosis after bleomycin treatment.
►Mer expression is restored by TAPI-0 treatment in bleomycin-stimulated lung. ►Mer signaling is enhanced by TAPI-0 treatment in bleomycin-stimulated lung. ►TAPI-0 enhances efferocytosis and promotes resolution of lung injury.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>22687607</pmid><doi>10.1016/j.taap.2012.05.024</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-008X |
ispartof | Toxicology and applied pharmacology, 2012-08, Vol.263 (1), p.61-72 |
issn | 0041-008X 1096-0333 |
language | eng |
recordid | cdi_osti_scitechconnect_22215882 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | 60 APPLIED LIFE SCIENCES ACETATES Acute Lung Injury - chemically induced Acute Lung Injury - prevention & control ADAM Proteins - drug effects ADAM Proteins - metabolism ADAM17 Protein Animals Antibiotics, Antineoplastic - pharmacology APOPTOSIS Apoptosis - drug effects Apoptotic cell clearance Biological and medical sciences BLEOMYCIN Bleomycin - pharmacology Blotting, Western Caspase 3 - metabolism Caspase 9 - drug effects CLEARANCE Dipeptides - pharmacology DNA Damage - drug effects ENZYME IMMUNOASSAY Enzyme-Linked Immunosorbent Assay GROWTH FACTORS Hydroxamic Acids - pharmacology INFLAMMATION INJURIES LACTATE DEHYDROGENASE Lung injury LUNGS MACROPHAGES Male Medical sciences Mer receptor tyrosine kinase MICE Mice, Inbred C57BL Phagocytosis - drug effects Receptor Protein-Tyrosine Kinases - drug effects Receptor Protein-Tyrosine Kinases - metabolism Receptor Protein-Tyrosine Kinases - physiology RECEPTORS Reverse Transcriptase Polymerase Chain Reaction TAPI-0 Toxicology TYROSINE |
title | Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T14%3A37%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preventing%20cleavage%20of%20Mer%20promotes%20efferocytosis%20and%20suppresses%20acute%20lung%20injury%20in%20bleomycin%20treated%20mice&rft.jtitle=Toxicology%20and%20applied%20pharmacology&rft.au=Lee,%20Ye-Ji&rft.date=2012-08-15&rft.volume=263&rft.issue=1&rft.spage=61&rft.epage=72&rft.pages=61-72&rft.issn=0041-008X&rft.eissn=1096-0333&rft.coden=TXAPA9&rft_id=info:doi/10.1016/j.taap.2012.05.024&rft_dat=%3Cpubmed_osti_%3E22687607%3C/pubmed_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/22687607&rft_els_id=S0041008X12002499&rfr_iscdi=true |